Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovidâs most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). Source
No articles found.
Natural Health Trends Corporation (NASDAQ: NHTC) is an international direct-sellin...
Natural Health Trends Corporation (NASDAQ: NHTC...
Novocure is a global oncology company working to extend survival in some of the mo...
Novocure is a global oncology company working t...
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and ...
Catalyst Pharmaceuticals is a biopharmaceutical...
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...
IMV Inc. is a clinical stage biopharmaceutical ...
Join the National Investor Network and get the latest information with your interests in mind.